A3IS: A novel broad-spectrum antimicrobial medicine
The A3IS platform has been developed as a topical medicine intended for the treatment of several infectious diseases with a clear focus in the area of dermatology-based indications.
Our Technology
Our first indication for the A3IS platform technology is fungal nail
infection, also known as onychomycosis. Mycosinate™, a specific formulation that is ideal for the treatment of fungal nail disease, was developed from the A3IS platform.
Nektr Technologies are currently in late-stage clinical development with
the Mycosinate® technology.
Due to A3IS’s broad- spectrum antimicrobial activity and excellent
safety profile on skin, there are several other indications which we are
currently pursuing for A3IS that are at an earlier stage of development.
Mycosinate®
The novel treatment for fungal nail infection
How does A3IS work?
Intended for the treatment of several infectious diseases
R&D Pipeline
Learn about our past work and upcoming indications
Contact Us
Do you have questions about Nektr or our technology? Connect with us using the details below or get in touch by filling out the form. We are happy to answer your questions!
Finisklin Business & Technology Park,
Sligo, Ireland, F91 HF66